Your browser doesn't support javascript.
loading
Continuous subcutaneous insulin infusion alters microRNA expression and glycaemic variability in children with type 1 diabetes.
Scott, Emma S; Januszewski, Andrzej S; Carroll, Luke M; Fulcher, Gregory R; Joglekar, Mugdha V; Hardikar, Anandwardhan A; Jones, Timothy W; Davis, Elizabeth A; Jenkins, Alicia J.
Afiliação
  • Scott ES; NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Januszewski AS; Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
  • Carroll LM; NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Fulcher GR; Department of Medicine, St Vincent's Hospital, University of Melbourne, Melbourne, Australia.
  • Joglekar MV; NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Hardikar AA; Department of Endocrinology and Diabetes, Royal North Shore Hospital, Sydney, Australia.
  • Jones TW; Northern Clinical School, University of Sydney, Sydney, Australia.
  • Davis EA; NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
  • Jenkins AJ; NHMRC Clinical Trials Centre, Faculty of Medicine and Health, University of Sydney, Sydney, Australia.
Sci Rep ; 11(1): 16656, 2021 08 17.
Article em En | MEDLINE | ID: mdl-34404828
ABSTRACT
To determine whether continuous subcutaneous insulin infusion (CSII) vs. multiple daily injections (MDI) therapy from near-diagnosis of type 1 diabetes is associated with reduced glycaemic variability (GV) and altered microRNA (miRNAs) expression. Adolescents (74% male) within 3-months of diabetes diagnosis (n = 27) were randomized to CSII (n = 12) or MDI. HbA1c, 1-5-Anhydroglucitol (1,5-AG), high sensitivity C-peptide and a custom TaqMan qPCR panel of 52 miRNAs were measured at baseline and follow-up (median (LQ-UQ); 535 (519-563) days). There were no significant differences between groups in baseline or follow-up HbA1c or C-peptide, nor baseline miRNAs. Mean ± SD 1,5-AG improved with CSII vs. MDI (3.1 ± 4.1 vs. - 2.2 ± - 7.0 mg/ml respectively, P = 0.029). On follow-up 11 miRNAs associated with diabetes vascular complications had altered expression in CSII-users. Early CSII vs. MDI use is associated with lower GV and less adverse vascular-related miRNAs. Relationships with future complications are of interest.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / Diabetes Mellitus Tipo 1 / Hipoglicemiantes / Insulina Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Sci Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: MicroRNAs / Diabetes Mellitus Tipo 1 / Hipoglicemiantes / Insulina Tipo de estudo: Clinical_trials Limite: Adolescent / Child / Female / Humans / Male Idioma: En Revista: Sci Rep Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Austrália